semaglutide news In the original clinical trials looking at (the GLP-1 in Novo Nordisk's Ozempic and Wegovy) and tirzepatide (in Eli Lilly's Mounjaro and Zepbound), patients gained back most of the weight after Older Americans Quit Weight Loss

Retatrutide : The triple-agonist (GLP-1 + GIP + Glucagon)

Set realistic expectations Harbstreet says its important to manage expectations you can do all of the above and still put weight back on

Single-dose vials launched in 2024 at lower price points than the multi-dose pens

Multiple Daily Pulses Protocols that model two or three administrations per day extend the same logic across the waking period, attempting to reinforce additional natural pulses

Peptides that modulate BDNF and neuroinflammatory pathways can theoretically interact with cortisol regulation, thyroid function, and sex hormone balance, but without multi-month hormone panels tracked in controlled cohorts, we're speculating